UROTHELIAL CARCINOMA RECURRENT
Clinical trials for UROTHELIAL CARCINOMA RECURRENT explained in plain language.
Never miss a new study
Get alerted when new UROTHELIAL CARCINOMA RECURRENT trials appear
Sign up with your email to follow new studies for UROTHELIAL CARCINOMA RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a Bladder-Instilled biologic keep recurrent bladder cancer at bay?
Disease control Not yet recruitingThis early-phase trial is testing a new biologic drug, UGN-501, for people whose non-muscle invasive bladder cancer has returned after previous treatment. The drug is given directly into the bladder through a catheter once a week for six weeks, with possible quarterly maintenance…
Matched conditions: UROTHELIAL CARCINOMA RECURRENT
Phase: PHASE1 • Sponsor: UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New bladder cancer drug could spare patients from bladder removal
Disease control Not yet recruitingThis Phase 3 trial tests NDV-01, a sustained-release combination of two chemotherapy drugs (gemcitabine and docetaxel), given directly into the bladder. It aims to prevent cancer from coming back in people with non-muscle invasive bladder cancer, including those who have not resp…
Matched conditions: UROTHELIAL CARCINOMA RECURRENT
Phase: PHASE3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC